This makes it an excellent biomarker for prostate cancer, and various reports detail the use of antibodies, aptamers, and small molecules attached to nanoparticles in order to target PSMA on prostate cancer cells [23]. The gene discussed is FOLH1; the disease is prostate carcinoma.